Valneva/$VALN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Valneva
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Ticker
$VALN
Sector
Primary listing
Employees
674
Headquarters
Website
Valneva Metrics
BasicAdvanced
$501m
-
-$0.91
1.40
-
Price and volume
Market cap
$501m
Beta
1.4
52-week high
$12.25
52-week low
$5.06
Average daily volume
36k
Financial strength
Current ratio
2.138
Quick ratio
1.225
Long term debt to equity
245.758
Total debt to equity
273.152
Interest coverage (TTM)
-2.42%
Profitability
EBITDA (TTM)
-93.926
Gross margin (TTM)
-25.27%
Net profit margin (TTM)
-88.30%
Operating margin (TTM)
-63.56%
Effective tax rate (TTM)
-0.31%
Revenue per employee (TTM)
$263,830
Management effectiveness
Return on assets (TTM)
-14.54%
Return on equity (TTM)
-109.57%
Valuation
Price to revenue (TTM)
5.228
Price to book
5.35
Price to tangible book (TTM)
7.46
Price to free cash flow (TTM)
-16.914
Free cash flow yield (TTM)
-5.91%
Free cash flow per share (TTM)
-0.318
Growth
Revenue change (TTM)
-15.98%
Earnings per share change (TTM)
46.93%
3-year revenue growth (CAGR)
-25.16%
10-year revenue growth (CAGR)
5.85%
3-year earnings per share growth (CAGR)
-10.33%
10-year earnings per share growth (CAGR)
5.22%
Valneva News
AllArticlesVideos
Valneva Q1 Earnings Call Highlights
MarketBeat·1 month ago
An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive
WSJ·3 months ago
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
WSJ·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs